News

Oslo, 9 September 2022 – Observe Medical ASA (“the Company” or “Observe Medical”), is pleased to announce the appointment of Carsten Trygve Bøgh as Chief Technology Officer (CTO), effective 2 October 2022. Mr. Bøgh has a long-standing medtech career, having led several innovative product launches, delivered impactful results, and reached value-inflection milestones for companies. “We…

Oslo, September 5, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter (in Norwegian). The letter to our shareholders is enclosed to this…

Oslo, 25 August 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today release its results for the second quarter and first half year of  2022. Following the acquisition of Biim Ultrasound in March 2022 and corresponding high corporate activity, Observe Medical has worked to integrate and extract operational synergies across the company and…

Oslo, 22 August 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), will release its second quarter and first half year 2022 results on Thursday, 25 August 2022. The presentation and report will be made available on NewsWeb and the Company’s website at 07:00 CET on the same day. Rune Nystad, CEO, and…

Observe Medical ASA has today, June 3, 2022, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com. For further information, please contact:   Rune Nystad, CEO Observe Medical Mobile:…

Oslo, 3 June 2022 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) today releases its first quarter results for 2022. Observe Medical has made progress across its medtech platform during the quarter, preparing and strengthening it for growth. The Company has also streamlined the organization and other operational synergies following the acquisition…

Oslo, 2 June 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical"or the "Company"), will release its first quarter results for 2022 on Friday, 3 June 2022. The presentation will be available on Newsweb and the Company’s website at 07:00 CET. Following the release, CEO, Rune Nystad and CFO, Per Arne Nygård will host a…

Oslo, May 13, 2022 – Observe Medical ASA (OSE:OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, June 3 2022 at 10:00 (CET). The annual general meeting will be held at Haakon VIIs gate 2, 0161 Oslo for those attending in person and via Lumi for those attending digitally. Voting…

Oslo, 29 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2021, which was approved by the board of directors on 28 April 2022. "It has been a transformational start to 2022, so I would like to take this opportunity to focus…

Oslo, 28 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that it has delivered an additional 58 Biim ultrasound probes to Fresenius Kidney Care in the US, completing the delivery of a total of 260 ultrasound probes in the first phase of the delivery to Fresenius Kidney Care as planned.…

Oslo, April 1, 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Sippi® Disposable Unit has received Medical Device Regulation Certification, ensuring continued market access for the unit in Europe after 2024.  Rune Nystad, CEO of Observe Medical, commented: "The MDR Certification confirms that the Sippi® Disposable Unit is compliant with…

Oslo, 29 March 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today releases a combined business update and interim financial results for the fourth quarter and full year 2021. Observe Medical can also report that 202 out of 260 Biim ultrasound probes have been successfully shipped. Another 58 Biim probes will be delivered…

The Board of Directors has today appointed Rune Nystad as Chief Executive Officer (CEO) of Observe Medical ASA  (the “Company” or “Observe Medical”), a Nordic medtech company with global reach. He succeeds Björn Larsson, who has headed the Company since 2019. Rune Nystad was previously the CEO of Biim Ultrasound, a company recently acquired by…

Oslo, March 28, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), will be announcing its fourth quarter 2021 results on Tuesday 29 March 2022. Members of the Management team will host a presentation at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. The live webcast will…

Oslo, 10 March 2022: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 8 March 2022 regarding the Company's completion of the acquisition of Biim Ultrasound AS and the issuance of 8,171,913 new shares in the Company as partial consideration to the sellers of Biim Ultrasound AS (the "Consideration…

Oslo, 8 March 2022: Observe Medical ASA (OSE: OBSRV) (the "Company" or Observe Medical") is excited to announce the completion of the acquisition of Biim Ultrasound AS ("Biim Ultrasound"), an international medical ultrasound technology company, adding another innovative product that improves patient welfare and outcome and that promotes positive health economics to its portfolio. With…

7 March 2022: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company ") on 24 February 2022, regarding the final result of the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per Offer Share (the "Rights Issue"). The…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 21 February 2022, regarding the exercise of subscription rights in the rights issue by certain primary insiders and a close associate of a primary insider, and today, on 24 February 2022 regarding the final results of the rights issue…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the "Rights Issue"). Thomas Grunfeld,…

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by Navamedic ASA. Reference is made to the previous stock exchange announcements from Observe Medical ASA (the "Company") announcing a fully underwritten rights issue of 25,714,286 new shares in the Company, raising gross proceeds of approximately NOK 180 million (the "Rights Issue"). In…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the "Rights Issue"). Thomas Grunfeld,…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of…

Oslo, February 21, 2022 – Observe Medical ASA (OSE: OBSRV) today announces a new order for Sippi systems, from our distributor in Poland, Skamex.    Observe Medical ASA (the "Company") has today, on 21 February 2022, received an order for  30 Sippi® Base units and 300 Sippi® Disposable units from Skamex. The total order value…

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by TopRidge Pharma (Ireland) Limited ("TopRidge Pharma"). Reference is made to the previous stock exchange announcements from Observe Medical ASA (the "Company") announcing a fully underwritten rights issue of 25,714,286 new shares in the Company, raising gross proceeds of approximately NOK 180 million…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue"). Please see the attached notifications of trade for information regarding the primary insiders' and their close associates' receipt of subscription…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Oslo, February 7, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter (in Norwegian) in relation to the fully underwritten rights issue in…

Issuer name: Observe Medical ASA Ex.date: 7 February 2022 Type of corporate action: Rights issue This information is published in accordance with the requirements of the Continuing Obligations.

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 14 January 2022 regarding a proposed fully underwritten rights issue in the Company (the "Rights Issue"). The extraordinary general meeting of the Company has today, on 4 February 2022, approved the Rights Issue and the authorisation to the board…

Reference is made to the key information relating to the preferential rights issue published by Observe Medical ASA (the "Company") on 14 January 2022. Please see below for updated key information relating to the preferential rights issue to be carried out by the Company: Date on which the terms and conditions of the preferential rights…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Oslo, 2 February 2022: In connection with the extraordinary general meeting of Observe Medical ASA (the "Company") to be held on 4 February 2022 (the "EGM"), Terje Bakken, chairman of the board of directors of the Company, has as at the close of trading on the Oslo Stock Exchange on 2 February 2022, received proxies…

· Observe Medical will develop and commercialize proprietary, innovative medtech products to the global market · International distributor and partner network with a Nordic direct sales organization · The agreement is set to accelerate the global commercial roll-out of the combined portfolio, including Sippi® US market launch and the entry of Biim in Europe Oslo,…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 14 January 2022, regarding the resolution by the Company's board of directors to propose that the Company carries out a share capital increase, by way of a fully underwritten rights issue, to raise gross proceeds of NOK…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

16 November 2021: The board of directors of Observe Medical ASA (the "Company") has resolved to grant 120,000 share options in the Company to the group CFO, Per Arne Nygård. Per Arne Nygård was engaged as interim CFO of the group as an consultant on 10 December 2019, and was permanently employed as CFO of…

Oslo, November, 3rd, 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the third quarter of 2021. The Company reports strong revenue growth for the Nordic portfolio, continued progress in the commercialization and go-to-market execution for Sippi® including an update on preparations for US market entry. CEO of Observe Medical,…

Observe Medical ASA invites you to a presentation of the third quarter 2021. The presentation will take place at Felix Konferansesenter in Oslo on Wednesday, November 3rd. The event will start at 08.30 CET and will be webcasted live on www.observemedical.com – Investor relations and at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20211103_5/ Representatives from the Company will…

Oslo, October 22, 2021 – Observe Medical ASA (OSE: OBSRV) continues its rollout of Sippi®, and reports clinical implementation at several sites in Europe – including use outside intensive care units, and clinical evaluations driving the health economic value of Sippi®  “We are excited to see Sippi® implementation gaining momentum as society and hospitals now…

FINANCIAL YEAR 2021 03.11.2021 – Quarterly Presentation – Q3 17.02.2022 – Quarterly Presentation – Q4 29.04.2022 – Annual Report 02.06.2022 – Annual General Meeting FINANCIAL YEAR 2022 12.05.2022 – Quarterly Presentation – Q1 25.08.2022 – Second quarter and Half-year Report 03.11.2022 – Quarterly Report – Q3 This information is published pursuant to the requirements set out…

Oslo, September 27th, 2021 – Observe Medical ASA (OSE: OBSRV) continues its rollout of Sippi®, and today announces that a major regional hospital in Italy has decided to implement Sippi® in the intensive care unit (ICU), with wireless connection to the hospital’s patient data management system. “The decision by a major Italian hospital to implement…

Oslo, August 20[th], 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the second quarter and first half-year of 2021, reporting continuous progress in the go-to-market execution for Sippi®, a unique and proprietary solution for digital, automated urine monitoring. “We have a sharp focus on continuous roll-out of Sippi®,…

Observe Medical ASA invites you to a presentation of the second quarter and first half year 2021. The presentation will take place at Felix Konferansesenter in Oslo on Friday, August 20th. The event will start at 08.30 CET and will be webcasted live on www.observemedical.com – Investor relations and at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20210820_3/  …

Oslo June 30, 2021 – Observe Medical ASA (OSE: OBSRV), today announces that it has entered into a distribution agreement and partnership with Skamex (Poland) for the launch of Sippi® in the Polish and the Romanian market. “We are pleased to announce that we are taking additional steps in the roll-out of Sippi® through our…